Menu

22nd Annual
San Diego Heart Failure Symposium for
Primary Care and Internal Medicine Physicians

New Strategies for Detection, Prevention and Treatment of Heart Failure
February 4 & 5, 2022
A Virtual Event from La Jolla, California

PROGRAM
Friday, February 4th

10:00am

Welcome and Introduction to the Symposium
Barry Greenberg, MD

SESSION I - Strategies for Preventing Heart Failure
Barry Greenberg, MD (Moderator)

10:10-10:25

Hypertensive Treatment to Reduce Heart Failure Risk
Christian Mende, MD

10:25-10:40

New Options for Reducing Lipids and CV Disease
Pam Taub, MD

10:40-10:55

Treating the Diabetic Patient; Evidence that CV and Renal Disease Can Be Prevented
Jia Shen, MD

10:55-11:10

Treating the Chronic Disease of Obesity - New and Emerging Options
Eduardo Grunvald, MD

11:10-11:25

Reduction in CV and Renal Events with Finerenone
Nick Wettersten, MD

11:25-11:55

Q/A and Panel Discussion
Michael J. Wilkinson, MD (Moderator)
Drs. Mende, Grunvald, Shen, Wettersten (Panelists)

12:00-1:00pm

Product Theatre I - Non-CME
A Treatment Option for Patients With HFrEF Following a Worsening HF Event
• Highlight the burden of HFH in patients with HFrEF.
• Review a treatment option for reducing the risk of HFH and CV death in patients with HFrEF. Featuring: Hirsch Mehta, MD - Associate Director for Advanced Heart Failure, Cardiac Transplantation, and Mechanical Circulatory Support at SHARP Healthcare
Director of the Pulmonary Hypertension Program at San Diego Cardiac Center.

Supported by: Merck

Please pre-Register for this Product Theatre by clicking on the following link:
Register
Once registered please use the link sent to your e-mail to access the program. If participants pre-register prior to the event they can avoid waiting for the link during the actual conference.

1:00-1:20

Break/Visit Virtual Exhibit Hall

SESSION II - SUPPORTED CE SEMINAR

1:20-2:20

Pulmonary Arterial Hypertension and Post-Capillary Pulmonary Hypertension Related to Left Heart Disease
Barry Greenberg, MD

Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson

2:20-3:20

Product Theatre II - Non-CME
XARELTO® 2.5 MG Vascular Dose: Reduction in the Risk of Major Cardiovascular Events in Patients With Chronic CAD or PAD
Featuring: Steven Kang, MD, Stanford Health Care
Supported by: Janssen

3:20-3:40

Break/Visit Virtual Exhibit Hall

SESSION III - Cardiac Hypertrophy, Amyloid and Other Infiltrative Diseases
Marcus Anthony Urey, MD (Moderator)

3:40-3:55

New Options for Treating HFpEF
Barry Greenberg, MD

3:55-4:10

Identifying and Managing Patients with Hypertrophic Cardiomyopathy
Jorge Silva Enciso, MD

4:10-4:25

Advances in the Management of Amyloid Disease
Marcus Anthony Urey, MD

4:25-4:40

Treating Pulmonary Artery Hypertension
Demosthenes Papamatheakis, MD

4:40-4:55

Using Biomarkers to Recognize and Management Heart Failure
Lori Daniels, MD

4:55-5:15

Case Discussion
Marcus Anthony Urey, MD (Presenter)
Drs. Greenberg, Silva Enciso, Papamatheakis and Daniels (Panelists)

5:15

Adjourn Day 1


Saturday, February 5th

8:15am

Welcome and Introduction to Day 2
Barry Greenberg, MD

SESSION IV - Optimizing Treatment of Patients with HFrEF
Barry Greenberg, MD (Moderator)

8:25-8:40

Expanding Role for ARNI Therapy
Gregg Fonarow, MD

8:40-8:55

SGLT2 Inhibitors: The New Pillar of Heart Failure Therapy
Javed Butler, MD

8:55-9:10

Vericiguat: The New Kid on the Block
Barry Greenberg, MD

9:10-9:25

Treating Hyperkalemia in Patients with Heart Failure and Renal Disease
Uri Elkayam, MD

9:25-9:40

What Do The Guidelines Tell Us About Treatment of HFrEF
Clyde Yancy, MD

9:40-9:55

No Therapy is Effective Unless Taken – How to Implement GDMT
Nancy Albert, RN, PhD

9:55-10:20

Case Presentation and Discussion
Barry Greenberg, MD (Moderator)
Drs. Fonarow, Butler, Elkayam, Albert, Yancy and Trina Huynh, PharmD (Panelists)

10:20

Break/Visit Virtual Exhibit Hall

SESSION V - Advances in Heart Failure Management
Eric Adler, MD (Moderator)

10:45-11:00

Recognizing and Overcoming Disparities in Care
Clyde Yancy, MD

11:00-11:15

2022 Update on Cardiac Transplant
Eric Adler, MD

11:15-11:30

New Approaches for Treating Heart Failure: Focus on Omecamtiv Mecarbil
John Teerlink, MD

11:30–11:45

Advances in Gene and Cell Therapies: Results of Recent Studies
Barry Greenberg, MD

11:45-12:15pm

Q/A and Panel Discussion
Eric Adler, MD (Moderator)
Drs. Yancy, Teerlink, Greenberg (Panelists)

12:25-1:25pm

Product Theatre III - Non-CME
A Treatment Option for Patients with Heart Failure with Reduced Ejection Fraction
Featuring: Warren Fegenbush, PharmD, BCPS
Supported by: AstraZeneca

1:25

Break/Visit Virtual Exhibit Hall

SESSION VI - Anticoagulation, Arrhthymias, Pacemakers and Remote Monitoring
Ulrika Birgersdotter Green, MD (Moderator)

1:45-2:00

The Expanding Role of DOAC’s in Treating Patients with CV Disease
Daniel Blanchard, MD

2:00-2:15

Role of the Wearable Cardioverter Defibrillator (WCD) in Preventing SCD
Kurt Hoffmayer, MD

2:15-2:30

Advances in Pacemakers and Defibrillators
Ulrika Birgersdotter Green, MD

2:30-2:45

Managing Atrial Fibrillation: Rate vs Rhythm, New Approaches for Preventing Thromboemboli
Jonathan Hsu, MD

2:45-3:00

Case Presentation and Panel Discussion
Ulrika Birgersdotter Green, MD (Presenter)
Drs. Hoffmayer, Hsu (Panelists)

3:00-3:15

Break/Visit Virtual Exhibit Hall

SESSION VII - Advanced Heart Failure
Barry Greenberg MD (Moderator)

3:15-3:30

Update on COVID-19 and Heart Failure
Eric Adler, MD

3:30-3:45

LVAD’s to Improve Longevity and QOL of Heart Failure Patients
Kimberly Hong, MD

3:45-4:00

Which Patients Are Candidates for Percutaneous MV and TV Interventions?
Ryan Reeves, MD

4:00-4:15

Remote Monitoring For Early Detection of Decompensation
Hao (Howie) Tran, MD

4:15-4:45

Presentation of Interesting Echo’s and Other Fascinomas
Daniel Blanchard, MD (Presenter)
Faculty and Audience (Panelists)

4:45

Adjourn until 2023